Pearl Steinzor

A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab over 2 years.

Interclass biologic switching can improve outcomes, but it also increases infection rates.

Artificial intelligence–powered insulin dosing and virtual coaching offer faster answers and convenience, but accuracy and oversight are key to building trust.

A new partnership delivers a scalable Fast Healthcare Interoperability Resources solution to help payers meet CMS' Interoperability and Prior Authorization Final Rule by 2027.

A new report from Bluesight reveals how automation and analytics are helping hospital pharmacy teams cut spending, manage shortages, and streamline procurement.

Robert F. Kennedy Jr halted 22 mRNA vaccine initiatives, drawing criticism from health experts over pandemic preparedness concerns.

A study finds 70 years may be a key cutoff for oxaliplatin benefit in stage III colorectal cancer, with no survival advantage seen in older patients or those with stage II disease.

Clearer information on fertility, heredity, and medication use is necessary during family planning for patients with psoriasis.

Adults with type 2 diabetes, especially those in vulnerable groups, face higher risks of medical debt, low credit scores, and bankruptcy.

Digital patient profiles and expansive real-world data are reshaping oncology clinical trials, explained Gen Li, PhD, MBA, president and founder of Phesi.

A randomized trial finds that default mailed outreach outperforms active choice strategies for initiating colorectal cancer screening in young adults.

Experts highlight advances in therapies, research on skin of color, and the impact of social determinants of health at the Society for Pediatric Dermatology's milestone annual meeting.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

Proper placement, device understanding, and ongoing support are key to helping children and adolescents with diabetes benefit from continuous glucose monitors (CGMs), explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.

A New Zealand study finds patients are open to remote and general practitioner-led care when it is tailored to their needs.

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

The study aims to build an accurate, interpretable model for stage III colorectal cancer prognosis.

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

Two posters presented at the Society for Pediatric Dermatology's Annual Meeting explore the psychological toll and potential nutritional approaches for managing vitiligo in children and adolescents.

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

Culturally informed, patient-centered strategies are needed to address acne and hyperpigmentation in patients with skin of color.

New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.

The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

Mental health, care of acute and chronic conditions, primary care access and prevention, and maternal and perinatal health were identified as key focus areas among a majority of states.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.

The Society for Pediatric Dermatology’s 50th Annual Meeting will highlight advances in pediatric skin, hair, and nail care, with expert-led sessions on cutting-edge research and therapies.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.